Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 4/20 | 0.46 |
| ▸ | PIM1 | P11309 | 2/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.43 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 3/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31227086 | 0.91 | BTK (0.46) | BTKPIM1PIM2USP30ANO1 | |
| SCHEMBL31227631 | 0.90 | BTK (0.47) | BTKPIM1PIM2USP30ANO1 | |
| SCHEMBL31227036 | 0.88 | BTK (0.45) | BTKPIM1PIM2USP30ANO1 | |
| SCHEMBL31227770 | 0.85 | PIM1 (0.43) | BTKPIM1PIM2USP30ANO1 | |
| SCHEMBL31227760 | 0.85 | BTK (0.46) | BTKPIM1PIM2USP30ANO1 | |
| SCHEMBL31227283 | 0.84 | BTK (0.47) | BTKPIM1PIM2USP30ANO1 | |
| SCHEMBL31227249 | 0.82 | PIM1 (0.49) | BTKPIM1PIM2USP30JAK3 | |
| SCHEMBL31227054 | 0.82 | PIM1 (0.49) | BTKPIM1PIM2USP30JAK3 | |
| SCHEMBL31227548 | 0.82 | PIM1 (0.49) | BTKPIM1PIM2USP30JAK3 | |
| SCHEMBL21599048 | 0.82 | ANO1 (0.47) | BTKPIM1PIM2USP30ANO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | BTK 4542/4885PIM1 709/4885PIM2 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.